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Abstract The expression of the inducible haem oxygenase
(HO-1) gene was examined in different skeletal muscles. Rats
were treated with haemin and a time course of HO-1 mRNA
expression was determined in soleus and extensor digitorum
longus (EDL) muscles. Fibre type composition and tissue
myoglobin content were also measured. We found that HO-1
mRNA expression markedly increased in soleus (type I fibres)
muscle but was only slightly affected in EDL (type II fibres).
HO-1 expression directly correlated with both percentage of red
fibres and tissue myoglobin. These data demonstrate that HO-1
gene expression follows a fibre type-specific pattern which might
indicate an important role for this protein in the maintenance of
skeletal muscle function.
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1. Introduction
Haem oxygenase is a ubiquitous microsomal enzyme that
catalyses the breakdown of haem to carbon monoxide (CO)
and biliverdin, the latter being converted to bilirubin by the
cytosolic biliverdin reductase [1]. The inducible isoform of
haem oxygenase (HO-1 or HSP32) is susceptible to up-regu-
lation in di¡erent tissues by a diversity of stress-related agents
and conditions, including ultraviolet radiations [2], hypoxia
[3], ischaemia-reperfusion [4], nitric oxide (NO) donors [5^9],
peroxynitrite [7,10], as well as its own substrate haemin [1]
and various haemoglobins [11,12]. Data from our own and
other laboratories have demonstrated that both haem oxygen-
ase-derived CO and bilirubin act as important e¡ector mole-
cules in the control of vessel contractility [13,14] and in
protection against oxidant-mediated cytotoxicity [10,15], re-
spectively. Recently, Essig and co-workers reported that
HO-1 mRNA increases in rat skeletal muscle following exer-
cise [16] and we have shown that cultured skeletal muscle cells
have the ability to up-regulate the expression of HO-1 when
appropriately stimulated by haemin and NO donors [8]. How-
ever, only limited information is available on the possible
physiological role of HO-1 induction in skeletal muscle.
Three main types of skeletal muscle ¢bres have been iden-
ti¢ed and are generally referred to as type I (slow-twitch ox-
idative), IIA (fast-twitch oxidative) and IIB (fast-twitch gly-
colytic) ¢bres [17]. Traditionally, they can also be
distinguished as red (type I and IIA) and white (type IIB)
¢bres. The numerous biochemical and ultrastructural di¡er-
ences between the various ¢bre types determine distinct meta-
bolic and physiological functions in a given muscle. For in-
stance, type I ¢bres have a low contraction speed and low
glycolytic capacity, and are characterised by a higher content
in mitochondria and myoglobin compared to type IIB ¢bres.
In addition, type I ¢bres are well supplied with capillaries and
are adapted for continuous work output with slow develop-
ment of fatigue, whereas type IIB ¢bres rely mainly on stored
glycogen and have low resistance to fatigue. Another peculiar
feature of skeletal muscle tissue is the expression of important
regulatory proteins which also appear to be con¢ned to spe-
ci¢c ¢bre types. In fact, recent studies have revealed that rat
skeletal muscle contains neuronal NO synthase and that NO
synthase protein and activity correlate strongly with type II
¢bre composition [18]. Furthermore, heat shock proteins
(HSPs), which function as molecular chaperones and are
highly induced in stress conditions, are expressed predomi-
nantly in type I ¢bres [19,20]. These ¢ndings prompted us
to investigate whether treatment of rats with haemin results
in skeletal muscle HO-1 (HSP32) induction and whether HO-1
gene expression follows a ¢bre type-speci¢c pattern.
2. Materials and methods
2.1. Materials
Male Sprague-Dawley rats were bred within our institution and
used in all studies. Haemin was obtained from Porphyrin Products
Inc. (Logan, UT, USA). Stock solutions of haemin were prepared by
dissolving the compound in 0.02 M NaOH and then adjusting the pH
to 7.4 by addition of 0.01 M phosphate bu¡er. [K-32P]dCTP was
obtained from Amersham International (Little Chalfont, Bucking-
hamshire, UK). All other reagents were obtained from Sigma-Aldrich
(Poole, Dorset, UK) unless otherwise speci¢ed.
2.2. Animal treatment
Rats (400^500 g) were injected intraperitoneally either with haemin
solution (10 mg/kg) or with vehicle (control group). Animals were
returned to their cages and were allowed free access to drink and
food. For HO-1 gene expression studies, animals were killed at vari-
ous time points (2, 4, 6 and 24 h) following haemin or vehicle injec-
tion. Soleus and extensor digitorum longus (EDL) skeletal muscles
were removed and immediately stored in liquid nitrogen until RNA
extraction. A second group of haemin-treated animals was used to
measure tissue myoglobin content, whereas the determination of ¢bre
type composition was performed in skeletal muscles of untreated rats.
2.3. RNA extraction and Northern blot analysis
Freshly removed rat soleus and EDL muscle tissues were snap-fro-
zen in liquid nitrogen and ground in a mortar and pestle. Total RNA
was extracted by phenol-chloroform using the method described by
Chomczynski and Sacchi [21]. Total RNA (10 Wg/lane) was run on a
1.3% denaturing agarose gel containing 2.2 M formaldehyde and
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transferred onto a nylon membrane, according to the method of Tyr-
rell and Basu Modak [22]. The membrane was hybridised using [K-
32P]dCTP-labelled cDNA probes to the rat HO-1 gene (the 88^971
nucleotide residue fragment of the rat haem oxygenase gene) [23] and
rat GAPDH gene. The hybridised membrane was exposed to radio-
graphic ¢lm and bands quanti¢ed by densitometric analysis.
2.4. Fibre type determination
Soleus and EDL rat muscle specimens were mounted on small cork
discs and snap-frozen in melting isopentane. Frozen sections (10 mm
thick) were cut by means of a cryostat at 320‡C and then allowed to
dry at room temperature for 4 h before staining. Sections were
mounted on slides and stained for ATPase activity at pH 4.5, 4.8
and 9.4, and NAD diaphorase activity using standard methods as
previously described [24,25]. Slides were viewed using a conventional
microscope (Olympus BX 40F, Olympus Optical Co., Tokyo, Japan)
at a magni¢cation of 40^200U. Five areas were selected at random
from each section and all ¢bres within the ¢eld of view were counted.
Three separate groups of ¢bres were clearly identi¢able, correspond-
ing to type I, type IIA and type IIB ¢bres.
2.5. Myoglobin measurements
Myoglobin content in soleus and EDL muscles was determined
using a previously described technique [26]. Brie£y, 200 mg of freshly
extracted muscle was ground in a mortar under liquid nitrogen and
suspended in 2 ml phosphate bu¡er (20 mM K2HPO4 ; pH 6.6). Sam-
ples were homogenised using a glass-Te£on homogeniser and then
centrifuged at 28 000Ug for 50 min. The supernatant was transferred
to a capped tube and CO gas was slowly bubbled through it (25 ml/
min) for 10 min. The absorbance at 538 and 568 nm of each sample
was measured against a blank containing phosphate bu¡er. The con-
centration of myoglobin was calculated from the di¡erence between
the two readings and expressed as mg/g wet tissue.
2.6. Statistical analysis
Data were analysed by one-way analysis of variance followed by
Bonferroni t-test. Di¡erences were considered signi¢cant at P 6 0.05.
3. Results
HO-1 mRNA expression following haemin treatment was
markedly di¡erent in soleus and EDL muscles (Fig. 1A). A
signi¢cant increase in HO-1 gene expression was found in
soleus, with maximal induction observed at 4 h after haemin
treatment (Fig. 1B). At 24 h, HO-1 expression had decreased
but was still greater than control. In contrast, haemin treat-
ment produced only a slight response in EDL muscle and
HO-1 mRNA levels were found to be elevated at 4 h after
haemin treatment but the increase was much less pronounced
than in soleus (Fig. 1B).
The ¢bre type composition of EDL and soleus muscles was
determined by staining for pH-sensitive ATPase and NAD
diaphorase activities and values from the two methods were
averaged. As shown in Table 1, soleus was con¢rmed to be
composed predominantly of type I ¢bre (91%) with much less
type IIA ¢bres (7%), making it a primarily red ¢bre muscle
(type I+type IIA = 98%). Type IIB (white) ¢bres in soleus
muscle represented only 1.5%. In contrast, EDL muscle was
composed mainly of type IIB (white) ¢bres (54%). Red ¢bres
in EDL muscle represented 46.5% of the total and were pri-
marily of type IIA (41%) with little type I (5.5%). Measure-
ments of tissue myoglobin content revealed that the tissue
composed primarily of red (type I and IIA) ¢bres, the soleus
muscle, had the highest concentration (Table 1). From a mean
of six samples, soleus contained 5.01 þ 0.78 mg/g wet tissue of
myoglobin, whereas EDL contained only 2.14 þ 0.25 mg/g wet
tissue. Interestingly, there was a direct correlation between
HO-1 mRNA expression and both percentage of red ¢bres
Fig. 1. A: Time course of HO-1 mRNA expression in rat muscles
following haemin treatment. Rats were injected intraperitoneally
with haemin (10 mg/kg) and total RNA was extracted from soleus
and EDL muscles at the times indicated after injection. Control ani-
mals were injected with an equivalent volume of vehicle and har-
vested after 6 h (lane C). Northern blot analysis was performed for
HO-1 and GAPDH genes as described in Section 2. B: Densitomet-
ric determination of relative HO-1 mRNA expression in soleus and
EDL muscles following treatment of animals with haemin.
Table 1
Fibre type composition and tissue myoglobin content of rat soleus and EDL muscles
Muscle Staining method Fibre type (%) Myoglobin (mg/g wet tissue) HO-1 mRNA (relative units)
Type I Type IIA Type IIB
Soleus NAD diaphorase 89 þ 3.4 9 þ 1.8 2 þ 1.2 ^ ^
ATPase 94 þ 3.7 5 þ 1.6 1 þ 1.1 ^ ^
Average 91 þ 3.5 7 þ 1.7 1.5 þ 1.1 5.01 þ 0.78 27
EDL NAD diaphorase 4 þ 1.7 37 þ 3.6 59 þ 2.6 ^ ^
ATPase 7 þ 2.0 45 þ 2.4 48 þ 1.8 ^ ^
Average 5.5 þ 1.9 41 þ 3.0 54 þ 2.2 2.14 þ 0.25 2
Fibre type composition was determined by NAD diaphorase and ATPase staining techniques (see Section 2). The relative increase in muscle
HO-1 mRNA expression after treatment of animals with 10 mg/kg haemin (4 h) is also indicated. Values are expressed as mean þ S.E.M. of six
independent experiments. Data shown for the ATPase staining method are the mean of values obtained at pH 9.4, 4.8 and 4.5.
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and myoglobin concentration in skeletal muscles (Table 1). As
shown, a more pronounced HO-1 mRNA expression was ob-
served in skeletal muscles with a higher proportion of red
¢bres and a greater myoglobin content.
4. Discussion
In recent years, several studies have been investigating the
biological role of haem oxygenase enzymes in di¡erent tissues.
However, little is known about the regulation of these en-
zymes in skeletal muscle. Here, we report that a marked in-
crease in the expression of the inducible isoform of haem oxy-
genase (HO-1) occurs in skeletal muscle in vivo after
treatment of rats with haemin. This ¢nding is not surprising
since haem is a potent inducer of HO-1 in all tissues examined
so far [1], and we have recently shown that in vitro exposure
of skeletal muscle cells to haemin is associated with a time-
dependent increase in HO-1 gene, protein expression and ac-
tivity [8]. In addition, up-regulation of HO-1 mRNA has been
detected in rat skeletal muscle tissue following exercise [16].
The novelty of the present study is, however, represented by
the result showing that HO-1 induction in skeletal muscle
follows a ¢bre type-speci¢c pattern. We found that HO-1 is
expressed predominantly in soleus muscle, which contains a
high percentage of red ¢bres (type I and IIA), whereas HO-1
mRNA in EDL (type IIB) was only slightly a¡ected. It is also
interesting to note that HO-1 mRNA levels directly correlated
with the amount of tissue myoglobin in the given muscles.
The ¢bre type speci¢city in the expression of certain genes
could be an intrinsic characteristic of skeletal muscle tissue.
Indeed, previous studies have shown that the stress protein
HSP60 is expressed more in red (type I) than in white (type
IIB) muscle [19]. Constitutive HSP72 protein levels are also
high in rat soleus muscle and their content is proportional to
the percentage of type I ¢bres in muscles of mixed ¢bre type
[20]. In addition, the levels of inducible HSP72 continuously
accumulate in the soleus following exercise, while they rise
only transiently in EDL [27]. Notably, numerous studies
have shown that soleus muscle and, in general, muscles rich
in type I ¢bres are more resistant to oxidative injury mediated
by ischaemia-reperfusion than either EDL or other muscles
composed primarily of type IIB ¢bres [28^30]. This increased
resistance may be partly explained by the di¡erential expres-
sion of intracellular defensive systems, such as the above-men-
tioned HSPs, which act as molecular chaperones for the cor-
rect folding of native and damaged proteins. According to our
data, HO-1 could also play a crucial role in the maintenance
of soleus muscle functions for multiple reasons. Firstly, in-
creased bilirubin production following HO-1 induction would
provide an e⁄cient and potent antioxidant system against free
radical-mediated damage [10,31]. Indeed, experimental evi-
dence from our laboratory supports a direct involvement of
HO-1-derived bilirubin in the amelioration of post-ischaemic
function in cardiac muscle (Clark et al., unpublished observa-
tion). Secondly, HO-1-derived CO appears to modulate vas-
cular tone during stress conditions [13,14] and, in the case of
soleus muscle (¢bre I), it may have an important role in reg-
ulating microcirculatory functions [9]. In this context, it is
tempting to speculate that CO and NO may act as signalling
molecules following ¢bre type-speci¢c patterns as skeletal
muscle contains a neuronal-type NO synthase restricted to
the sarcolemma of type II ¢bres [18]. Finally, our ¢ndings
that HO-1 up-regulation is con¢ned to red ¢bres and directly
correlates with high myoglobin content might have an impor-
tant biological signi¢cance. In fact, the haem moiety of my-
oglobin is a suitable substrate for haem oxygenase as it has
been reported that myoglobin is degraded in vivo under con-
ditions of increased haem oxygenase activity [32].
Thus, our study is the ¢rst to demonstrate that HO-1 in-
duction follows a ¢bre type-speci¢c pattern suggesting an im-
portant role for haem oxygenase in the catabolism of haem-
dependent proteins and its contribution in the maintenance of
skeletal muscle functions.
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